mathbiology

FROM EARLY DETECTION TO PEAK PERFORMANCE.

The first non-invasive **metabolic screening PLATFORM** for **Clinical, Sports & Longevity applications.**

NON-INVASIVE | PORTABLE | AI-BASED

THE CHALLENGE

TOO LATE DIAGNOSIS

1 out of 3

visits have **unexplained symptoms**

40% cancers

diagnosed too late

10% deaths

caused by **diagnostic errors**

up to 12 weeks

to determine **a therapy is effective**

mathbiology

THE CHALLENGE

Cost of getting it wrong

Diagnostic Errors Cost

$200B
per year in US

€120B
per year in EU

Cost of Unexplained Symptoms

$300B
per year in US

€100B
per year in EU

Sources: Johns Hopkins, NIH, NHS England, OECD, BMJ Quality & Safety (model-based estimates including direct + indirect cost).

mathbiology

THE CHALLENGE

SAME SYMPTOMS, DIFFERENT FATE.

Heartburn



Stomach CANCER

Heartburn



Gastro-duodenal DYSBIOSIS / Helicobacter

Heartburn



GASTRIC PYROSIS

Heartburn



SPINAL Pathology

The real challenge: **identifying the root cause**

mathbiology

THE CHALLENGE

Each patabology has its own metabolic fingerprint.

Our DMA ® (Deep Metabolic Assessment) Technology captures a disease's biological fingerprint by measuring bioelectrical responses to biomarkers.

HOW OUR TECHNOLOGY WORKS



1

ACQUIRE

Non-invasive probes capture natural **bioelectrical currents** at **60** predefined **points** on the skin.



2

PROTOCOLS

The app guides the operator through standardized investigation **protocols**. A visits lasts **15–60 minutes**.



3

ANALYZE

Cloud-based **AI algorithms** analyze acquired bioelectrical signals.



4

REPORT

A personalized health report is generated, including a structured, **multi-level set of health indices**.

mathbiology

APPLICATIONS

One Technology multiple applications

01 **CLINICS** — Screen. Explain. Detect early.

Connects unexplained symptoms to root causes, enables early diagnosis, personalized care, and treatment monitoring.

02 **SPORT & PERFORMANCE** — Measure. Optimize. Protect.

The DMA® Performance vertical profiles each athlete's unique physiological signature to optimize training, recovery.

03 **WELLNESS & LONGEVITY** — Prevent. Sustain. Extend healthspan.

Longitudinal metabolic monitoring that identifies weaknesses before symptoms appear and supports proactive health.



BEFORE SYMPTOMS, BEFORE DECLINE, BEFORE LIMITS.

The first non-invasive, **PORTABLE** AI-powered platform that reads the body's bioelectrical signals to reveal metabolic status **before symptoms, decline & limits.**

A single device, many protocols.

DMA® ANALYSIS
Up to 600
metabolic parameters in one visit

SPATIAL RESOLUTION
62 Points
measured across the body

TEST DURATION
15–60 min
fast and comfortable

METABOLIC INDEX
BMRi
actionable health indices



OUR TECHNOLOGY

What It Is vs. What It Is Not

- ✓ It detects early functional deviations
- ✓ It supports clinical decision-making
- ✓ It enables repeatable, non-invasive screening
- ✓ Portable - Easy to use - non-Invasive

- ✗ It does not replace imaging or lab tests
- ✗ It does not issue standalone diagnoses
- ✗ It does not autonomously guide treatment

REAL WORLD EVIDENCES

VALIDATION

1,300+

People Involved in Validation

25,000+

Protocols Acquired

2M+

Data-Points Collected in Our Database

Retrospective Cross-Diseases:
Sensitivity/PPA (Positive Percent Agreement> 95%


TRACTION

- 3 Clinical Trials Ongoing (Oncology & Cardiology) joined with University of Salerno. Completion: Nov 2026
- 4 Clinical Trials in pipel
- Research network: CNR (Italian National Research Center) + University of Salerno + Campus Biomedico
- ine for 2027
- An anchor community of about 500 subjects
- Advanced talks with tennis club clusters totaling about 7,200 members.

mathbiology

EXAMPLES in ONCOLOGY

DMA® IN ONCOLOGY




Exploratory study: not designed to assess diagnostic performance, but to observe whether systemic metabolic patterns could be detected.


Understanding cancer through DMA®

The figure demonstrates a clear (>4x) separation between:

- healthy individuals and
- oncological patients

based on the Cumulative Bioelectrical Marker Response Index (c-BMRi).





Understanding cancer through DMA®

HEALTHY SUBJECT

Low, balanced signals maintaining physiological homeostasis.



7.93
BMRi Index

PATIENT UNDER CHEMOTHERAPY


Chemotherapy helps to partially normalise these electrical signals, the values remain higher than those found in the healthy control group.



12.25
BMRi Index

UNTREATED ONCOLOGICAL PATIENT

Malignancy is identified by a significant surge in metabolic activity that disrupts the body's natural state of homeostasis.



36.45
BMRi Index

One Platform multiple regulatory pathways

OUR PRODUCTS

SCREENING

- Prevention
- Longevity
- Clinical Supportive information

Market Ready

MDR CLASS 1

MONITORING

- Supportive monitoring of health status

Market Ready

MDR CLASS 1

PERFORMANCE

- Sport & High Performance People

Market Ready

NON MEDICAL DEVICE

DIAGNOSTICS

- Vertical Diagnostics Support Protocols

In progress

MDR CLASS 2

mathbiology

REGULATORY TRACTION

De-Risking Growth Through Regulatory Excellence.

Same platform, multiple regulatory pathways.

2023

CE Certification for Electromagnetic Compatibility (EMC)
.

2026

DMA Performance Available

DMA ® Screening -MDR Class 1 Oct 2026

Certification for **ISO-13-485 Certif. Ready for auditing.**

2027

DMA ® Diagnostics - MDR Class 2 Available.

U.S. Food and Drug Administration (FDA) submission **for DMA ® Screening**

Insurance-reimbursement coding pathways started

2028

U.S. Food and Drug Administration (FDA) submission **for DMA ® Diagnostics**

Insurance- reimbursement coding.

mathbiology

We Complement Existing Diagnostics

MARKET COMPARISON


	NON -INVASIVE	MULTI-ORGAN APPLICABILITY	DESIGNED FOR FREQUENT MONITORING	INSIGHTS INTO BIOCHEMICAL PROCESSES	SUPPORTS PREVENTIVE CARE	ENABLES EARLY DISEASE DETECTION	EASY DEPLOYMENT & PORTABILITY
Blood tests	✗	✗	✗	✓	✓	✗	✗
Eco	✓	✗	✓	✗	✓	✗	✓
PET, CAT, BMD	✗	✗	✗	✗	✗	✗	✗
ECG / EGG	✓	✗	✓	✗	✓	✗	✓
Biopsy	✗	✓	✗	✓	✗	✗	✗
Math Biology	✓	✓	✓	✓	✓	✓	✓

Team


Our founders and partners bring extensive experience from **multinational pharmaceutical companies**, the **AI sector, academia** and successful **entrepreneurial ventures**.They are supported by an international team of scientific advisors, researchers and healthcare industry experts, all committed to advancing our vision.

WHO WE ARE


BUSINESS & GOVERNANCE



RAFFAELE MACCIONI
CEO & CTO,
Pres. DSA (AI Ass.)



MARIA CRISTINA CARACCIOLO
PhD - Legal & Corporate Affairs



ALESSANDRO CASCIA
CFO



MADDALENA MAZZALI
Marketing & Community Manager




TED MATWIJEC
US Market Advisor



MAURIZIO CATELLANI
Market Strategy & Development

BIOCLINIC RESEARCH



GIUSEPPE SGRO
Biology & Clinical R&D Director Former R&D Dir. Pfizer



FRANCESCA A. AIELLO
Scientific Coordinator - postdoc in Biochemical Pathways and Health Innovation



LUCA EVANGELISTI
Biologist



ROBERTA NOCERINO
Postdoctoral Researcher




ALESSIA STEFANELLI
Postdoctoral Researcher




IDA PAVESE
Oncologist - Specialist Advisor


TECH & REGULATORY



RAFFAELE CERULLI
Scientific Advisors
Prof. Univ. Salerno



EMANUELE CARPANZANO
Scientific Advisors
Prof. Univ. SUPSI



ROBERTO TUFANO
CEAI Specialist PhD student
Univ. Salerno




GIAMPIERO BARTOLOMEI
Regulatory Engineer

mathbiology

SCALING THROUGH A TECH-AS-SERVICE MODEL


MARKET SIZE



mathbiology

DMA® PERFORMANCE

DEEP METABOLIC ASSESSMENT for Sport & High Performance People



Underperformance starts before symptoms.
We start before underperformance.

Non-invasive metabolic screening platform for performance optimization.

mathbiology

THE CHALLENGE

THE PERFORMANCE SIGNALS WE MISS

1 in 3

of elite athletes experience overreaching in their career

12–15%

sprint performance drop after 3 matches / <72h recovery

2.3×

higher injury risk with ≥2 matches/week

>70%

of overtrained athletes show undetected stress signs



Source PubMed /PMC o Frontiers in Physiology.

mathbiology

THE PROTOCOL

The triad analysis framework

01 **Mental Readiness** - Perform Under Pressure

Focus, resilience, ability to adapt

02 **Recovery & Early Risk Signals** - Recover. Adapt. Improve.

Recovery, inflammation, physiological response

03 **Performance Support** - Fueling Peak Performance

Energy availability, muscle efficiency, and electrolyte balance.



THE REPORT APP

HIGH-PERFORMANCE PROGRAM

Great — you're officially in the High-Performance Program. This is your first DMA® check-in: from here, every session builds your personal profile and helps get you on court in your best condition.

DMA® PERFORMANCE REPORT

ID9818 · Pre Match

Your body speaks, we know how to listen.

In one line: mental readiness is **well-regulated**; the profile is driven by high **energetic & electrolyte demand** — Magnesium, T3, Potassium — concentrated in the **right chest–shoulder chain**. Pre-match focus: **hydration, electrolytes and energy availability**.

DATE	DOMINANT SIDE	PROTOCOL
22 Jul 2026 · 16:27	Right	Tennis · Muscle-joint chain

4	13	4	~10′
Districts	Biomarkers	Active markers	Test time



THE BIG PICTURE

The Performance Triad

The 13 markers tell one story across three dimensions. Here is the verdict for each, before any numbers.

Mental Readiness

Regulated

Stress, pressure and emotional recovery are **well contained**. CRF is slightly raised (normal pre-match arousal), cortisol stays baseline. No active markers.

- CRF 2.59
- Cortisol 1.06

Recovery & Adaptation

Watch · 1 active

Recovery demand is mostly moderate, with one **focal inflammatory signal** (TNF-α) in the core/front-leg district and mild oxidative fatigue (MDA). Worth following in recovery, **not a sign of injury**.

- TNF-α 3.20 *
- MDA 2.83
- IL-6 2.59
- CPK 1.67
- PGE-2 1.57

Performance Support

Dominant · 3 active

This is the headline. High energetic & electrolyte demand: Magnesium and T3 in **marked activation**, Potassium significant. Points to hydration, electrolytes and energy availability around the match.

- Magnesium 4.63 *
- T3 4.43 *
- Potassium 3.36 *
- Insulin 2.97
- Iron 2.17
- Leucine 2.04



INVESTMENT ASK

An Opportunity to Transform Global Healthcare Together

ASK

$12M

SAFE available for qualified Investors

USE OF FUNDS

Clinical Validation & Regulatory	35%
Go-To-Market	30%
Team & Tech Edition 2.0	25%
G&A, IP & Working Capital	10%

YOUR BODY SPEAKS. WE LISTEN.

mathbiology

YOUR BODY SPEAKS, WE LISTEN.

Medical Screening Platform to explain
Symptoms & Detect Disease Earlier.

Alessandro Cascia
Math Biology CFO
alessandro.cascia@mathbiology.tech
+39 339 2757936

